Airborne pays $7 mln in settlement with 32 states
CHICAGO (Reuters) - Airborne Health Inc has agreed to pay $7 million to settle investigations by 32 state attorneys general and the District of Columbia over the past marketing and labeling of its products.
Airborne did not admit any wrongdoing in the settlement. It previously settled two matters involving similar claims.
The privately held company makes popular dietary supplements with vitamins, minerals and herbs that it says help support the immune system.
“We’re putting the dietary supplement industry on notice — snake oil sales pitches will no longer be given free reign,” Connecticut Attorney General Richard Blumenthal said in a statement. “Our strong coalition of states will continue to investigate and pursue companies that make false claims about dietary supplements and other products.”
The agreement will not impact Airborne’s products “because it deals with language that had already been dropped from our advertising and labeling,” Airborne Founder and Chief Executive Victoria Knight-McDowell said in a statement.
“Even though we believe the legal claims against Airborne were unjustified, we wanted to close the book on these legal and regulatory issues.”
According to Blumenthal, Airborne agreed to certain prohibitions against making claims over the benefits of its products. The company also may not demand where a retailer puts its products in stores, he said.
Blumenthal also said Airborne agreed not to market a product with directions that would result in a person ingesting 15,000 International Units of Vitamin A or more per day.
Airborne previously reached a $23.5 million settlement of a class action lawsuit and a $6.5 million settlement with the Federal Trade Commission. The company said the FTC settlement funds would be paid only if the class action settlement does not cover all consumer claims submitted by September 18.
(Reporting by Jessica Wohl; Editing by Andre Grenon)
--------------------------------------------------------------------------------------------Related Posts:
WASHINGTON (Reuters) - Diabetic supply maker Bayer Healthcare, a unit of Bayer AG, has agreed to pay $97.5 million to settle allegations that it paid kickbacks to several diabetic suppliers and caused them to submit false Medicare claims, the U.S. Justice Department said on Tuesday. Bayer agreed to enter into a corporate integrity agreement - which
Full Post: Bayer Healthcare in $97.5 million kickback settlement
--------------------------------------------------------------------------------------------
Review Summary To put it simply, this company is a brand of dietary supplements, most of which are advertised to lead to weight loss. In fact, this company claims to be the weight loss and wellness leader since 1992. When it comes to their weight loss aids, this company appears to promote products that contain trendy
Full Post: Fit America - Diet Products For Weight Loss
--------------------------------------------------------------------------------------------
WASHINGTON (Reuters) - A U.S. consumer group said Thursday it filed a class action lawsuit against Coca-Cola Co, accusing the company of making deceptive health claims about its VitaminWater beverages. The Center for Science in the Public Interest (CSPI) said Coke made a range of claims that go beyond those allowed by the Food and Drug
Full Post: U.S. group sues Coke over VitaminWater health claims
--------------------------------------------------------------------------------------------
BOSTON (Reuters) - Bristol-Myers Squibb Co said on Tuesday it agreed to pay $1.1 million to settle charges connected with an anti-trust investigation by the New York State Attorney General’s Office, Last year, Bristol-Myers pleaded guilty to two federal criminal counts related to allegations that it illegally concealed a side deal with the generic drugmaker Apotex
Full Post: Bristol-Myers settles Plavix case with states
--------------------------------------------------------------------------------------------
By Ransdell Pierson NEW YORK (Reuters) - Pfizer Inc said on Friday it plans to pay $894 million to settle lawsuits alleging that its withdrawn Bextra painkiller and widely used Celebrex arthritis drug harmed U.S. patients and defrauded consumers. Pfizer said the money would be paid out under three separate tentative settlements — including one that resolves
Full Post: Pfizer to settle Bextra, Celebrex lawsuits